NASDAQ: APMAptorum Group Ltd Stock
$1.39-0.04 (-2.8%)
Updated Jan 10, 2025
APM Price
$1.39
Fair Value Price
N/A
Market Cap
$7.60M
52 Week Low
$0.46
52 Week High
$17.49
P/E
4.48x
P/B
0.34x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$18.66k
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.2
Operating Cash Flow
-$3M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APM Overview
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine APM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
D
Momentum
C
Sentiment
D
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
APM
Ranked#162 of 556
Ranked#162 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.25 | A | |
| $121.41 | A | |
| $5.27 | A |
Be the first to know about important APM news, forecast changes, insider trades & much more!
APM News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APM is good value based on its earnings relative to its share price (4.48x), compared to the US market average (30.06x)
P/E vs Market Valuation
APM is good value based on its earnings relative to its share price (4.48x), compared to the US Biotechnology industry average (-113.93x)
P/E vs Industry Valuation
APM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more APM due diligence checks available for Premium users.
Valuation
APM fair value
Fair Value of APM stock based on Discounted Cash Flow (DCF)
Price
$1.39
Fair Value
-$3.00
Undervalued by
146.29%
APM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
4.48x
Industry
-113.93x
Market
30.06x
APM is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
APM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
APM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
4.88x
APM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
APM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.7M
Liabilities
$4.5M
Debt to equity
0.2
APM's short-term assets ($1.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APM's long-term liabilities ($3.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
APM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
APM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APM vs Biotech Stocks
Aptorum Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.